Drug discovery collaboration for neurodegenerative diseaeses

0

The exploitation of Evotec‘s unique induced pluripotent stem cell (“iPSC”) platform for the systematic drug screening in patient-derived disease models is at the centre of the new strategic collaboration agreement signed with Celgene Corporation. The project will initially address Amyotrophic lateral sclerosis, Alzheimer’s disease, Parkinson’s disease, and multiple other neurodegenerative disorders. Evotec will receive an upfront payment of $ 45 million, while Celgene holds exclusive options to in-license worldwide rights to Evotec programmes developed from the company’s compound library.

 

SHARE

LEAVE A REPLY

Please enter your comment!
Please enter your name here